ArticleAntibiotics (Basel, Switzerland)2023
Multidrug-Resistant ESBL-Producing
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Implementing the CRISPR 2.1 array for genotyping enhances identification of uropathogenic Escherichia coli in Colombian pediatric patients.Biomedica : revista del Instituto Nacional de Salud · 2026Article
- Antibiofilm Potential and Mechanisms ofMicroorganisms · 2026Article
- Genomic profiling of extended-spectrum beta-lactamase-producing Escherichia coli isolated from poultry and poultry farm workers in Accra, Ghana.Scientific reports · 2026Article
- Phenotypic and molecular characterization of Salmonella enterica isolated from retail beef in Peshawar, Pakistan.PloS one · 2026Article
- Interdisciplinary insights on selection, surveillance and mitigations of antimicrobial resistance dynamics on a UK dairy farm with relevance to other one health sectors.Frontiers in veterinary science · 2026Review
- Seasonal prevalence of extended-spectrum β-lactamase-producing bacteria in food-chain animals, humans, and the surrounding environment in Fayoum governorate: a one health approach.Frontiers in microbiology · 2026Article
- Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.BMC infectious diseases · 2025Article
- Antimicrobial resistance profiles and detection of mecA, blaCTX-M-1, and blaSHV genes in bacteria among diabetic foot ulcer patients from selected referral hospitals in Uganda.BMC infectious diseases · 2025Article
- Antimicrobial resistance and molecular characterization of ESBL-producing Enterobacterales from Parirenyatwa Hospital wastewater in Harare.JAC-antimicrobial resistance · 2025Article
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- Shelter dogs as reservoirs of international clones of Escherichia coli carrying mcr-1.1 and blaVeterinary microbiology · 2025Article
- Antimicrobial Stewardship Impact on Antibiotic Use in Three Tertiary Hospitals in Zambia: A Comparative Point Prevalence Survey.Antibiotics (Basel, Switzerland) · 2025Article
- Prevalent and Drug-Resistant Phenotypes and Genotypes ofInternational journal of molecular sciences · 2025Article
- Article
- Is It Time to Start Worrying? A Comprehensive Report on the Three-Year Prevalence of ESBL-Producing Bacteria and Their Trends in Antibiotic Resistance from the Largest University Hospital in Slovakia.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Investigating trends in antibiotic resistance ofMicrobiology (Reading, England) · 2024Article
- High Prevalence of ESBL Genes in CommensalGenes · 2024Article
- Extended-spectrum beta-lactamase-producingMicrobiology spectrum · 2024Article
- Multidrug-Resistant Extended-Spectrum Beta-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, cephalosporin therapy failure is a serious problem for infection control. One causative agent of cephalosporin-resistant infections is multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.